HOME > November 22, 2024
Daily News
November 22, 2024
- Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- COVID as a Lesson, Pfizer Exec Urges Govt to Draft Emergency Safety Management Guidelines
November 22, 2024
- Kyowa Kirin, Kura Form Global Collab on Leukemia Drug
November 22, 2024
- Pharma Pushes to Scrap Off-Year Revisions; LDP Members Urge Fresh Talks by 4 Ministers
November 22, 2024
- Alloy Inks Cell Therapy Deal with Takeda, Japan Outpost to Launch by Month-End
November 22, 2024
- Japan Pharmacy Group Demands Abolishing Off-Year Price Revisions
November 22, 2024
- Pfizer, Hokkaido Forge Comprehensive Healthcare Partnership
November 22, 2024
- Shionogi CEO Requests Higher Price for Medicon
November 22, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
